Search Results - "Baron, Ari"

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial by Sharma, Padmanee, Prof, Retz, Margitta, Prof, Siefker-Radtke, Arlene, MD, Baron, Ari, MD, Necchi, Andrea, MD, Bedke, Jens, Prof, Plimack, Elizabeth R, MD, Vaena, Daniel, MD, Grimm, Marc-Oliver, Prof, Bracarda, Sergio, MD, Arranz, José Ángel, MD, Pal, Sumanta, MD, Ohyama, Chikara, Prof, Saci, Abdel, PhD, Qu, Xiaotao, PhD, Lambert, Alexandre, PhD, Krishnan, Suba, MD, Azrilevich, Alex, PharmD, Galsky, Matthew D, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to…”
Get full text

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma by Finn, Richard S, Ikeda, Masafumi, Zhu, Andrew X, Sung, Max W, Baron, Ari D, Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E, Saito, Kenichi, Siegel, Abby B, Dubrovsky, Leonid, Mody, Kalgi, Llovet, Josep M

“…The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with…”
Get full text

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial by Zhu, Andrew X, Dr, Park, Joon Oh, MD, Ryoo, Baek-Yeol, MD, Yen, Chia-Jui, MD, Poon, Ronnie, MD, Pastorelli, Davide, MD, Blanc, Jean-Frederic, MD, Chung, Hyun Cheol, MD, Baron, Ari D, MD, Pfiffer, Tulio Eduardo Flesch, MD, Okusaka, Takuji, MD, Kubackova, Katerina, MD, Trojan, Jorg, MD, Sastre, Javier, PhD, Chau, Ian, MD, Chang, Shao-Chun, MD, Abada, Paolo B, MD, Yang, Ling, MS, Schwartz, Jonathan D, MD, Kudo, Masatoshi, MD

“…Summary Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1…”
Get full text

Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer by Danila, Daniel C, Szmulewitz, Russell Z, Vaishampayan, Ulka, Higano, Celestia S, Baron, Ari D, Gilbert, Houston N, Brunstein, Flavia, Milojic-Blair, Marija, Wang, Bei, Kabbarah, Omar, Mamounas, Michael, Fine, Bernard M, Maslyar, Daniel J, Ungewickell, Alexander, Scher, Howard I

“…Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1…”
Get full text

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study by Finn, Richard S, Kudo, Masatoshi, Cheng, Ann-Lii, Wyrwicz, Lucjan, Ngan, Roger K C, Blanc, Jean-Frederic, Baron, Ari D, Vogel, Arndt, Ikeda, Masafumi, Piscaglia, Fabio, Han, Kwang-Hyub, Qin, Shukui, Minoshima, Yukinori, Kanekiyo, Michio, Ren, Min, Dairiki, Ryo, Tamai, Toshiyuki, Dutcus, Corina E, Ikezawa, Hiroki, Funahashi, Yasuhiro, Evans, Thomas R Jeffry

“…In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma…”
Get full text

Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial by Freemantle, Nick, Mollon, Patrick, Meyer, Tim, Cheng, Ann-Lii, El-Khoueiry, Anthony B., Kelley, Robin K., Baron, Ari D., Benzaghou, Fawzi, Mangeshkar, Milan, Abou-Alfa, Ghassan K.

“…The CELESTIAL trial (NCT01908426) demonstrated overall survival benefit for cabozantinib versus placebo in patients with advanced hepatocellular carcinoma…”
Get full text

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study by Chau, Ian, Peck-Radosavljevic, Markus, Borg, Christophe, Malfertheiner, Peter, Seitz, Jean Francois, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frederic, Chung, Hyun Cheol, Baron, Ari D, Okusaka, Takuji, Bowman, L, Cui, Zhanglin Lin, Girvan, Allicia C, Abada, Paolo B, Yang, Ling, Zhu, Andrew X

“…Abstract Purpose To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled…”
Get full text

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study by Burstein, Harold J., Keshaviah, Aparna, Baron, Ari D., Hart, Ronald D., Lambert‐Falls, Rosemary, Marcom, P. Kelly, Gelman, Rebecca, Winer, Eric P.

“…BACKGROUND. The optimal trastuzumab‐based chemotherapy regimen for HER2‐overexpressing, metastatic breast cancer is not known. The trastuzumab and vinorelbine…”
Get full text

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer by Kim, Richard D., McDonough, Shannon, El-Khoueiry, Anthony B., Bekaii-Saab, Tanios S., Stein, Stacey M., Sahai, Vaibhav, Keogh, George P., Kim, Edward J., Baron, Ari D., Siegel, Abby B., Barzi, Afsaneh, Guthrie, Katherine A., Javle, Milind, Hochster, Howard

“…The rationale for the evaluation of trametinib in advanced biliary cancer (BC) is based on the presence of mitogen-activated protein kinase alterations and on…”
Get full text

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial by Kelley, RobinKate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L., Lim, HoYeong, Baron, Ari D., Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C., Milwee, Steven, El-Khoueiry, Anthony B., Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K.

“…In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with…”
Get full text

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 by Kudo, Masatoshi, Finn, Richard S, Ikeda, Masafumi, Sung, Max W, Baron, Ari D, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Meyer, Tim, Nagao, Satoshi, Saito, Kenichi, Mody, Kalgi, Ramji, Zahra, Dubrovsky, Leonid, Llovet, Josep M

“…Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3…”
Get full text

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia by Treon, Steven P, Soumerai, Jacob D, Branagan, Andrew R, Hunter, Zachary R, Patterson, Christopher J, Ioakimidis, Leukothea, Chu, Luis, Musto, Paul, Baron, Ari D, Nunnink, Johannes C, Kash, Joseph J, Terjanian, Terenig O, Hyman, Paul M, Nawfel, Elena L, Sharon, David J, Munshi, Nikhil C, Anderson, Kenneth C

“…Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We…”
Get full text

Characterization and Management of Adverse Reactions in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib by Jones, Anna, Degregorio, Paola, Sung, Max W, Ramji, Zahra, Ren, Min, Baron, Ari D

“…Advanced practice providers (APPs) play a vital role in monitoring for and managing adverse reactions (ARs). As lenvatinib ARs can resemble cirrhosis (commonly…”
Get full text

Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma by Vogel, Arndt, Frenette, Catherine, Sung, Max, Daniele, Bruno, Baron, Ari, Chan, Stephen L., Blanc, Jean Frédéric, Tamai, Toshiyuki, Ren, Min, Lim, Howard J., Palmer, Daniel H., Takami, Yuko, Kudo, Masatoshi

“…Introduction: Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact…”
Get full text

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] by Chau, Ian, Peck-Radosavljevic, Markus, Borg, Christophe, Malfertheiner, Peter, Seitz, Jean Francois, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frederic, Chung, Hyun Cheol, Baron, Ari D., Okusaka, Takuji, Bowman, L., Cui, Zhanglin Lin, Girvan, Allicia C., Abada, Paolo B., Yang, Ling, Zhu, Andrew X.

Get full text

Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates by King, Daniel A, Smith, Amber R, Pineda, Gino, Nakano, Michitaka, Michelini, Flavia, Goedegebuure, S Peter, Thyparambil, Sheeno, Liao, Wei-Li, McCormick, Aaron, Ju, Jihang, Cioffi, Michele, Zhang, Xiuli, Hundal, Jasreet, Griffith, Malachi, Grandori, Carla, Pollastro, Maddy, Rosati, Rachele, Margossian, Astrid, Chatterjee, Payel, Ainge, Trevor, Flory, Marta, Ocampo, Paolo, Chen, Lee-May, Poultsides, George A, Baron, Ari D, Chang, Daniel T, Herman, Joseph M, Gillanders, William E, Park, Haeseong, Hoos, William A, Nichols, Mike, Fisher, George A, Kuo, Calvin J

Get more information

INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial by Patt, Yehuda Z., Murad, Waheed, Fekrazad, Mohammed H., Baron, Ari D., Bansal, Pranshu, Boumber, Yanis, Steinberg, Kim, Lee, Sang‐Joon, Bedrick, Ed, Du, Ruofei, Lee, Fa Chyi

“…Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC)…”
Get full text

A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma by Ross, Helen J., Hart, Lowell L., Swanson, Paul M., Rarick, Mark U., Figlin, Robert A., Jacobs, Andrew D., McCune, David E., Rosenberg, Arthur H., Baron, Ari D., Grove, Laurie E., Thorn, Michael D., Miller, Dennis M., Drachman, Jonathan G., Rudin, Charles M.

“…Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC)…”
Get full text

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial by Kudo, Masatoshi, Finn, Richard S, Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Piscaglia, Fabio, Baron, Ari, Park, Joong-Won, Han, Guohong, Jassem, Jacek, Blanc, Jean Frederic, Vogel, Arndt, Komov, Dmitry, Evans, T R Jeffry, Lopez, Carlos, Dutcus, Corina, Guo, Matthew, Saito, Kenichi, Kraljevic, Silvija, Tamai, Toshiyuki, Ren, Min, Cheng, Ann-Lii

“…In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular…”
Get full text

Promoting multidisciplinary care for patients with unresectable hepatocellular carcinoma (HCC): Findings from a quality improvement initiative across two community cancer centers by Baron, Ari David, Delcuze, Bethany, Guzzone, Francesca, Carter, Jeffrey D., Heggen, Cherilyn

“…528 Background: Evolving treatment paradigms in HCC are increasing the need for multidisciplinary coordination and a focus on patient-centered care…”
Get full text